Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Patient advocacy session: Registries, databases and statistical modelling. Making MBC count : The new German Cancer Registry.

Marschner, N. 2017

The Breast, Volume 36, Supplement 1, 2017, Page S8.
https://doi.org/10.1016/S0960-9776(17)30617-3

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: / Journal: The Breast
Registerübergreifend
2017
MANTA: A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer.

Schmid, P., Ferreira, M., Dubey, S., Zaiss, M., Harper-Wynne, C., Makris, A., Brown, V., Kristeleit, H., Patel, G., Perelló, A., Jones, A., Mithal, N., Ruiz, I., Kümmel, S., Brunt, A.M., Guerra, J.A., Cao, M.G., Saura, C., Mousa, K., Sarker, S.-J., Coetzee, C., Swann, R., Cortes, J., 2016.

Cancer Res 76(4 Supplement), OT1-03-12-OT1-03-12. doi:10.1158/1538-7445.SABCS15-OT1-03-12

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: SABCS / Journal: Cancer Research
MANTA
2016
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma – a phase II trial.

Mey, U.J.M., Brugger, W., Schwarb, H., Pederiva, S., Schwarzer, A., Dechow, T., Jehner, P., Rauh, J., Taverna, C.J., Schmid, M., Schmidt-Hieber, M., Doerfel, S., Fischer, N., Ruefer, A., Ziske, C., Knauf, W., Cathomas, R., von Moos, R., Hitz, F., Sauter, R., Hiendlmeyer, E., Cantoni, N., Bargetzi, M., Driessen, C., 2016.

Br. J. Haematol. 176(5), 770–782. doi:10.1111/bjh.14481

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: - / Journal: British Journal of Hematology
BRd
2016
The PAZOREAL Non-Interventional Study to Assess Effectiveness and Safety of Pazopanib and Everolimus in the Changing Metastatic Renal Cell Carcinoma Treatment Landscape.

Goebell, P., Doehn, C., Grüllich, C., Steiner, T., Ehneß, R., Welslau, M., 2016.

Ann Oncol 27(suppl_6), 852P. doi:10.1093/annonc/mdw373

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: ESMO / Journal: Annals of Oncology
PAZOREAL
2016
A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO).

Sehouli, J., Tomè, O., Dimitrova, D., Camara, O., Runnebaum, I.B., Tessen, H.W., Rautenberg, B., Chekerov, R., Muallem, M.Z., Lux, M.P., Trarbach, T., Gitsch, G., 2016.

J. Cancer Res. Clin. Oncol. 143(3), 541–550. doi:10.1007/s00432-016-2307-0

Abstract

Indikation: Other, Sonstige / Veranstaltung: - / Journal: Journal of Cancer Research and Clinical Oncology
Treosulfan-Studie
2016
Dermatux: Phase IV trial of C-FOLFIRI in 1st-line metastatic colorectal cancer receiving a pre-defined skin care.

Schimanski, C.C., Staib, F., Goehler, T., Hebart, H.F., Neise, M., Rudi, J., Geer, T., Ehscheidt, P., Flohr, T., Schmittel, A.H., Galle, P.R., Moehler, M.H., 2016.

J Clin Oncol 34 (suppl; abstr e15048). doi:10.1200/JCO.2016.34.15_suppl.e15048

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
DERMATUX
2016
Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial.

Welt, A., Marschner, N., Lerchenmueller, C., Decker, T., Steffens, C.-C., Koehler, A., Depenbusch, R., Busies, S., Hegewisch-Becker, S., 2016.

Breast Cancer Res Treat 156, 97–107. doi:10.1007/s10549-016-3727-x

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Breast Cancer Research and Treatment
CARIN
2016
Antianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort – The Tumor Anemia Registry.

Steinmetz, T., Schröder, J., Plath, M., Link, H., Vogt, M., Frank, M., Marschner, N., 2016.

Anemia 2016, e8057650. doi:10.1155/2016/8057650

Abstract

Indikation: Supportive Therapy, Supportivtherapie / Veranstaltung: - / Journal: Anemia
TAR
2016
Patient-reported outcomes in elderly bevazizumab-treated primary ovarian cancer patients: OTILIA study on behalf of the north-eastern german society of gynaecological oncology.

Sehouli, J., Wimberger, P., Oskay-Oezcelik, G., Jungberg, P., Meinerz, W., Janssen, J., Keller, M., Richter, R., Harde, J., Klawitter, S., Wegenaer, A., Mueller, M., Mustea, A., 2016.

IGCS-0471

Indikation: Other, Sonstige / Veranstaltung: IGCS / Journal: -
OTILIA
2016
REASON: Klinisch-pathologische Faktoren relevant für die klinische Wirksamkeit von Gefitinib bei Patienten mit NSCLC Stadium IIIb/IV und mutiertem EGF Rezeptor (EGFR-M+).

Schuette, W., Eberhardt, W., Schirmacher, P., Dietel, M., Zirrgiebel, U., Radke, S., Thomas, M., 2016.

Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin P430.

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGP / Journal: -
REASON
2016